ESPR · Categories · Downgrades
ESPR - Analyst downgrades
Esperion Therapeutics Inc. (ESPR) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for ESPR
- Esperion Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Esperion Therapeutics from Buy to Neutral
- Esperion Therapeutics downgraded by BofA Securities with a new price targetBofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $2.50
- Esperion Therapeutics downgraded by BofA SecuritiesBofA Securities downgraded Esperion Therapeutics from Buy to Neutral
- Esperion Therapeutics downgraded by Northland Capital with a new price targetNorthland Capital downgraded Esperion Therapeutics from Market Perform to Under Perform and set a new price target of $1.00
- Esperion Therapeutics downgraded by BofA Securities with a new price targetBofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $1.50 from $8.00 previously
- Esperion Therapeutics downgraded by Credit Suisse with a new price targetCredit Suisse downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $6.00 from $7.00 previously
- Esperion Therapeutics downgraded by Credit Suisse with a new price targetCredit Suisse downgraded Esperion Therapeutics from Outperform to Neutral and set a new price target of $11.00 from $28.00 previously
- Esperion Therapeutics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Esperion Therapeutics from Equal-Weight to Underweight and set a new price target of $11.00
- Esperion Therapeutics downgraded by Stifel with a new price targetStifel downgraded Esperion Therapeutics from Buy to Hold and set a new price target of $20.00 from $37.00 previously
- Esperion Therapeutics downgraded by Jefferies Financial GroupJefferies Financial Group downgraded Esperion Therapeutics from Buy to Hold
- Esperion Therapeutics downgraded by Jefferies with a new price targetJefferies downgraded Esperion Therapeutics from Buy to Hold and set a new price target of $30.00 from $40.00 previously
- Esperion Therapeutics downgraded by The Goldman Sachs Group with a new price targetThe Goldman Sachs Group downgraded Esperion Therapeutics from Neutral to Sell and set a new price target of $24.00 from $44.00 previously
- Esperion Therapeutics downgraded by Goldman with a new price targetGoldman downgraded Esperion Therapeutics from Neutral to Sell and set a new price target of $24.00 from $44.00 previously